Top Markets
#1 MowCat MowCat +48.94%
#2 Bermuda Shorts Bermuda Shorts +25.42%
#3 aPriori aPriori +21.46%
#4 Biconomy Biconomy +19.82%
#5 Derive Derive +19.05%
#6 Velvet Velvet +18.18%
#7 Quack AI Quack AI +17.27%
#8 Audiera Audiera +15.85%
#9 Perle Perle +14.87%
#10 Palladium Network Palladium Network +13.69%
Coin of the day
MowCat MowCat
設定
言語
日本
通貨
USD
テーマ
IMV Inc. IMV Inc.

IMV Inc.

IMV
株式のランク #35289
IMV Inc. is a clinical-stage biotechnology company dedicated to the development... IMV Inc. is a clinical-stage biotechnology company dedicated to the development of innovative immunotherapies. The company utilizes its proprietary DPX immune-educating technology platform to create a portfolio of treatments for various solid and hematological cancers. Its leading investigational drug, maveropepimut-S, is a DPX-based immunotherapy designed to target cancer cells that express survivin. Maveropepimut-S is currently undergoing Phase II clinical trials for diffuse large B-cell lymphoma, ovarian cancer, and specific bladder, liver, and microsatellite instability-high tumors, with Phase I trials also active for breast cancer. Beyond its primary candidate, IMV is also advancing DPX-SurMAGE, which is in Phase I clinical trials for bladder cancer, and is developing DPX-COVID-19 and DPX-RSV to address infectious diseases. Originally founded in 2000 as Immunovaccine Inc., the company adopted the name IMV Inc. in May 2018 and operates from its headquarters in Dartmouth, Canada.
株価
$0.82959892
最終同期: 2023-05-23
時価総額
$4.16M
変化（1日）
-0.04%
変化（1年）
0.00%
国
CA
取引 IMV Inc. (IMV)

カテゴリー

Healthcare
IMV Inc.（IMV）の利益
2026 時点の利益 TTM: 0
IMV Inc. の最新の財務報告によると、同社の現在の利益は 0 です。2026 年には 0 の利益を上げ、これは 2026 年の利益 0 と 同等 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
IMV Inc. の利益の推移（2026 〜 2026）
各年末の利益
年 利益 変化
提供された日付のデータは十分ではありません。
同業他社の利益
企業 利益 利益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
- -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
$3.01B -
BE